

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)						
1. Name and Address of Reporting Person <sup>*</sup> – Jones Jason C	2. Date of Event Requiring Statement (Month/Day/Year) 04/24/2019		3. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [EKSO]			
(Last) (First) (Middle) C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201	04/24/2017	Issuer (Check Director X_Officer (give t		er	5. If Amendment, Date Original Filed(Month/Day/Year)	
(Street) RICHMOND, CA 94804			below) below) VP of Product Development		6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person	
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned					
1. Title of Security     2. Amount       (Instr. 4)     Beneficiall       (Instr. 4)     (Instr. 4)			3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Natur (Instr. 5	re of Indirect Beneficial Ownership ;)	
Common Stock	12,500	12,500				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

				<b>P</b> ,	/			
	1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		Securities Underlying Derivative Security		or Exercise I Price of I Derivative	Form of	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Date Exercisable	Expiration Date	Title	Amount or Number of Shares	2	Direct (D) or Indirect (I) (Instr. 5)	
	Employee Stock Option (right to buy)	<u>(1)</u>	11/01/2028	Common Stock	200,000	\$ 2.05	D	

# **Reporting Owners**

		Relationships					
<b>Reporting Owner Name / Address</b>	Director	10% Owner	Officer	Other			
Jones Jason C C/O EKSO BIONICS HOLDINGS, INC. 1414 HARBOUR WAY SOUTH, SUITE 1201 RICHMOND, CA 94804			VP of Product Development				

# **Signatures**

/s/ Jason C. Jones	05/03/2019	
**Signature of Reporting Person	Date	

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option becomes exercisable as to 50,000 shares on October 15, 2019, and thereafter as to the remaining shares in 36 equal monthly installments on the 15th day of each month.

## **Remarks:**

No securities are beneficially owned.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.